Slide 1: PolyPeptide Group AG H1 2025 results presentation
PolyPeptide Group AG H1 2025 results presentation 12.08.2025 Baar Switzerland
Slide 2: Disclaimer
2 Disclaimer This presentation (the "Presentation") has been prepared by the Group operates. While the Group believes that such Alternative Financial Performance Measures (APM) PolyPeptide Group AG (“PolyPeptide” or the “Group”). The research and estimates are reasonable and reliable, they, and This
Slide 3: Q&A
Q&A The presentation will be followed by a Q&A session. Anyone who wishes to ask a question, or make a comment can do it in the following ways: • Through the telephone by pressing * and 1 (please register on the website to receive the personal dial-in details). In case of assistance please press * a
Slide 4: Agenda
Agenda 1 Business update Juan José González, CEO 2 H1 2025 financial results Marc Augustin, CFO 3 Guidance Juan José González, CEO 4 Q&A All 4
Slide 5: +24% growth in H1 2025, successful ramp-up at Belgian site and guidance
+24% growth in H1 2025, successful ramp-up at Belgian site and 2025 full-year guidance revised towards the upper end of the range Growth in revenue and cash flow • +23.7% revenue increase versus H1 2024 mainly driven by commercial revenue, specifically metabolic therapeutics • Strong operating cash
Slide 6: Peptides - one of the most attractive markets for CDMOs
Peptides - one of the most attractive markets for CDMOs Peptide drugs in clinical development (Phase I to III)1 Total 489, split by therapeutic area in % • Global peptide therapeutics market expected to grow with a compound annual growth rate of above 15% from Metabolic 2024 until 2030, largely driv
Slide 7: PolyPeptide is well-positioned with its global cGMP sites
PolyPeptide is well-positioned with its 6 global cGMP sites Multi-site network Torrance, US Malmö, SE Clinical and Clinical and commercial commercial manufacturing manufacturing Malmö (SE) San Diego, US Strasbourg, FR Braine-l’Alleud (BE) Clinical Clinical and Strasbourg (FR) Torrance (US) manufactu
Slide 8: Sharpened growth strategy
Sharpened growth strategy Vision Most innovative peptide CDMO Competitive Innovation Development Modularity Advantages Multi-site network Operational/quality Talent, culture, Foundation Industrial-scale capabilities excellence and sustainability 8
Slide 9: Business mix further shifting to metabolic and commercial revenue
Business mix further shifting to metabolic and commercial revenue Revenue by Therapeutic Area Revenue by Business Area2 (EUR m) (EUR m) CAGR1 CAGR1 12.9% 167 12.9% 167 135 51 135 -0.4% 59 7.5% Covid 32 Covid 32 22 9.7% Other 52 Development 44 108 16.4% Oncology 15 94 27.3% Commercial 59 Metabolic 36
Slide 10: Capacity expansion plans on track
Capacity expansion plans on track Today 2021 2024 2028 Maintenance (across sites) Debottlenecking Capacity Expansion Modularity Large-scale SPPS production in Braine-l’Alleud Ongoing work to double SPPS capacity in Strasbourg Ongoing work to double SPPS capacity in Malmö Illustrative project phases:
Slide 11: Continued focus on strengthening our organization and capabilities
Continued focus on strengthening our organization and capabilities • Appointment of Chief Manufacturing and Supply Chain Officer − Raoul Bernhardt, joining from Guerbet where he was Senior Vice President, Technical Operations. Formerly Vice President, Pharma Product Delivery Division at Catalent (a
Slide 12: Agenda
Agenda 1 Business update Juan José González, CEO 2 H1 2025 financial results Marc Augustin, CFO 3 Guidance Juan José González, CEO 4 Q&A All 12
Slide 13: Commercial business driving growth
Commercial business driving growth EUR m +23.7% +23.3% 167.1 166.5 0.6 • YoY revenue growth of 23.7%; 23.3% at 29.7 constant exchange rates • Commercial revenue up 37.9%, reflecting ramp-up of new large-scale capacity, as well 135.0 2.3 as favorable market trends across PolyPeptide’s portfolio • Dev
Slide 14: EBITDA continues to improve while ramping up new capacity
EBITDA continues to improve while ramping up new capacity EUR m 2.1% 4.6% 2.7% • Higher sales based on operational progress as well as large-scale SPPS ramp-up in 5.2 Braine • Product mix as well as higher FTE cost ahead of H2 2025 growth partially offset 14.5 4.5 positive development compared to H1
Slide 15: Further improved operating cash flow
Further improved operating cash flow EUR m Operating cash flow • Positive free cash flow based on disciplined working capital management and further 47.1 50.8 prepayments received from customers 76.7 • Net cash flow from investing activities of 68.3 2.5 10.0 EUR -50.8 m – finalization of large-scale
Slide 16: Multi-layered financing strategy for growth
Multi-layered financing strategy for growth Mid-term outlook: “Ensuring capacity also beyond 2028” 1 Improve profitability and cash flow 2 Customer funding support 3 Utilization of credit facilities 4 Equity instruments (as per AoA1) 1 The Company’s Articles of Association 16
Slide 17: Agenda
Agenda 1 Business update Juan José González, CEO 2 H1 2025 financial results Marc Augustin, CFO 3 Guidance Juan José González, CEO 4 Q&A All 17
Slide 18: We revise our guidance for 2025 towards the upper end of the range
We revise our guidance for 2025 towards the upper end of the range Previous Revised Priorities for 2025 remain unchanged Revenue • Execute operational and quality growth vs 2024 at CER 10-20% 13-20% excellence programs • Reach target utilization rate of large- scale SPPS asset in Belgium. High singl
Slide 19: Confirming PolyPeptide's mid-term outlook
Confirming PolyPeptide’s mid-term outlook • Strategy to be the most innovative peptide CDMO, anchored on three Double 2023 revenue by 2028 competitive advantages − Innovation focused on green chemistry and process intensification − Superior pipeline development EBITDA margin approaching 25% by 2028
Slide 20: Agenda
Agenda 1 Business update Juan José González, CEO 2 H1 2025 financial results Marc Augustin, CFO 3 Guidance Juan José González, CEO 4 Q&A All 20
Slide 21: Q&A
Q&A The presentation will be followed by a Q&A session. Anyone who wishes to ask a question, or make a comment can do it in the following ways: • Through the telephone by pressing * and 1 (please register on the website to receive the personal dial-in details) In case of assistance please press * an
Slide 22: *|% PolyPeptide
*|% PolyPeptide
Slide 23: Appendix
Appendix PolyPeptide Group AG polypeptide.com 23
Slide 24: Result for the period
Result for the period Summary P&L 30 June 2025 (unaudited) kEUR H1 2025 H1 2024 Financial result Revenue 167,096 135,043 • Unfavorable revaluation (unrealized) of intra- EBITDA 4,434 2,869 Group positions from foreign exchange movements impacted the reported net result margin % 2.7% 2.1% (favorable
Slide 25: Consolidated income statement
Consolidated income statement 1 January – 30 June (unaudited) 25
Slide 26: Consolidated statement of financial position
Consolidated statement of financial position As at 30 June (unaudited) 26
Slide 27: Consolidated statement cash flow
Consolidated statement cash flow 1 January – 30 June (unaudited) 27
Slide 28: Contact and calendar
Contact and calendar Contact Events 2025 Tim Brandl 13 August 2025 Zurich Roadshow with ZKB Director FP&A and Investor Relations 14 August 2025 London Roadshow with Barclays T: +41 435 020 580 E: tim.brandl@polypeptide.com 21 August 2025 U.S. Roadshow (virtual) with Morgan Stanley 8-10 September 202
Slide 29: Thank you
Thank you PolyPeptide Group AG polypeptide.com
Slide 30: *|% PolyPeptide
*|% PolyPeptide